Clinical efficacy analysis of Dendritic Cell-Cytokine Induced Killer Cell Immunotherapy Combined with Paclitaxel-Cisplatin Chemotherapy in patients with Advanced Ovarian Cancer. 2021

Yue Gao, and Yafei Hao, and Yuanyuan Jia
Department of Obstetrics and Gynecology, Affiliated Huai'an Hospital of Xuzhou Medical University and Second People's Hospital of Huai'an, Huai'an, China.

OBJECTIVE To explore the efficacy and safety of dendritic cell-cytokine induced killer cell (DC-CIK) immunotherapy combined with paclitaxel-cisplatin chemotherapy in the treatment of advanced ovarian cancer. METHODS Patients with advanced ovarian cancer formed the Chemotherapy group (paclitaxel-cisplatin, n=68) and the other 68 patients formed the DC-CIK group (DC-CIK + paclitaxel-cisplatin, n=68). The short-term efficacy and changes in the levels of immune function indexes, serum CD133 and DEAD-box helicase 4 (DDX4) were analyzed. RESULTS Both overall response rate (ORR) and disease control rate (DCR) in the DC-CIK group were significantly better than those in the Chemotherapy group. After treatment, the proportions of CD3+ T lymphocytes, CD3+ CD4+ T lymphocytes and NK cells and the CD4/CD8 ratio were evidently higher, while the proportion of CD4+ CD25+ T lymphocytes was evidently lower in the DC-CIK group than those in the Chemotherapy group. After treatment, the levels of basic fibroblast growth factor (bFGF), carbohydrate antigen 19-9 (CA19-9), CA125, human epididymis protein 4 (HE4), cytokeratin 19 fragment antigen 21-1 (CYFRA21-1), DDX4 and CD133 markedly declined in the two groups, and they were markedly lower in the DC-CIK group than in the Chemotherapy group. At 1 month after treatment, the score of emotional functioning in function module of QLQ-C30 scale was greatly higher in the DC-CIK group than that in the Chemotherapy group, while the score of nausea and vomiting in symptom module was greatly lower in the DC-CIK group than that in the Chemotherapy group. The follow-up analysis showed that the overall survival (OS) rate in the DC-CIK group was remarkably superior than in the Chemotherapy group. CONCLUSIONS DC-CIK immunotherapy combined with paclitaxel-cisplatin chemotherapy can greatly improve the clinical efficacy, enhance the immune function, reduce the levels of serum tumor markers, raise the quality of life and prolong the survival in patients with advanced ovarian cancer.

UI MeSH Term Description Entries
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D003713 Dendritic Cells Specialized cells of the hematopoietic system that have branch-like extensions. They are found throughout the lymphatic system, and in non-lymphoid tissues such as SKIN and the epithelia of the intestinal, respiratory, and reproductive tracts. They trap and process ANTIGENS, and present them to T-CELLS, thereby stimulating CELL-MEDIATED IMMUNITY. They are different from the non-hematopoietic FOLLICULAR DENDRITIC CELLS, which have a similar morphology and immune system function, but with respect to humoral immunity (ANTIBODY PRODUCTION). Dendritic Cells, Interdigitating,Interdigitating Cells,Plasmacytoid Dendritic Cells,Veiled Cells,Dendritic Cells, Interstitial,Dendritic Cells, Plasmacytoid,Interdigitating Dendritic Cells,Interstitial Dendritic Cells,Cell, Dendritic,Cell, Interdigitating,Cell, Interdigitating Dendritic,Cell, Interstitial Dendritic,Cell, Plasmacytoid Dendritic,Cell, Veiled,Cells, Dendritic,Cells, Interdigitating,Cells, Interdigitating Dendritic,Cells, Interstitial Dendritic,Cells, Plasmacytoid Dendritic,Cells, Veiled,Dendritic Cell,Dendritic Cell, Interdigitating,Dendritic Cell, Interstitial,Dendritic Cell, Plasmacytoid,Interdigitating Cell,Interdigitating Dendritic Cell,Interstitial Dendritic Cell,Plasmacytoid Dendritic Cell,Veiled Cell
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy
D017239 Paclitaxel A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS BREVIFOLIA. It stabilizes MICROTUBULES in their polymerized form leading to cell death. 7-epi-Taxol,Anzatax,Bris Taxol,NSC-125973,Onxol,Paclitaxel, (4 alpha)-Isomer,Paxene,Praxel,Taxol,Taxol A,7 epi Taxol,NSC 125973,NSC125973,Taxol, Bris
D055612 Cytokine-Induced Killer Cells Mononuclear leukocytes that have been expanded in CELL CULTURE and activated with CYTOKINES such as INTERLEUKIN-2 to produce large numbers of highly cytotoxic cells. CIK Cells,Lymphocyte-Activated Killer Cell,Lymphocyte-Activated Killer Cells,CIK Cell,Cell, Lymphocyte-Activated Killer,Cells, Lymphocyte-Activated Killer,Cytokine Induced Killer Cells,Cytokine-Induced Killer Cell,Killer Cell, Cytokine-Induced,Killer Cell, Lymphocyte-Activated,Killer Cells, Cytokine-Induced,Killer Cells, Lymphocyte-Activated,Lymphocyte Activated Killer Cell,Lymphocyte Activated Killer Cells

Related Publications

Yue Gao, and Yafei Hao, and Yuanyuan Jia
March 2019, Clinical cancer research : an official journal of the American Association for Cancer Research,
Yue Gao, and Yafei Hao, and Yuanyuan Jia
December 2012, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi,
Yue Gao, and Yafei Hao, and Yuanyuan Jia
September 2017, Clinical cancer research : an official journal of the American Association for Cancer Research,
Yue Gao, and Yafei Hao, and Yuanyuan Jia
January 2020, Journal of B.U.ON. : official journal of the Balkan Union of Oncology,
Yue Gao, and Yafei Hao, and Yuanyuan Jia
May 2014, Nan fang yi ke da xue xue bao = Journal of Southern Medical University,
Copied contents to your clipboard!